Antonelli G
Department of Biomedicine, University of Pisa, Italy.
J Biol Regul Homeost Agents. 1995 Oct-Dec;9(4):123-31.
Interferons (IFNs) are being increasingly used in the treatment of several disorders. Since the early clinical trials, it was documented that some of the patients who received IFN produced antibodies against it. Both neutralizing and nonneutralizing antibodies were detected and it was demonstrated that the development of neutralizing antibodies was often associated with a failure of the IFN therapy. This finding is not actually surprising if one considers that many papers describing natural or therapy-induced development of antibodies to IL-1, IL-2, IL-6, IL-10, G-CSF, GM-CSF, insulin, recombinant factor VIII in man have been published. Since hormones, cytokines, biological modifiers and homeostatic agents are being used for therapeutic applications, the awareness of the possibility that therapy-induced antibodies can develop in man should help define the therapeutic management of many infectious, autoimmune and neoplastic diseases. This paper will review and discuss what is currently known about the technical, biological, and clinical aspects of these "autoantibodies", with particular reference to antibodies to IFN developed during therapy.
干扰素（IFN）在多种疾病的治疗中应用日益广泛。自早期临床试验以来，有记录表明部分接受IFN治疗的患者会产生针对它的抗体。已检测到中和抗体和非中和抗体，并且证实中和抗体的产生常与IFN治疗失败相关。如果考虑到已发表了许多描述人体中针对白细胞介素 -1、白细胞介素 -2、白细胞介素 -6、白细胞介素 -10、粒细胞集落刺激因子（G-CSF）、粒细胞巨噬细胞集落刺激因子（GM-CSF）、胰岛素、重组凝血因子 VIII 的天然或治疗诱导性抗体产生的论文，那么这一发现实际上并不令人惊讶。由于激素、细胞因子、生物调节剂和内稳态因子正被用于治疗用途，认识到人体可能产生治疗诱导性抗体这一可能性，应有助于确定许多感染性、自身免疫性和肿瘤性疾病的治疗管理。本文将回顾并讨论目前已知的关于这些“自身抗体”的技术、生物学和临床方面的情况，尤其涉及治疗期间产生的针对IFN的抗体。
